FIELD: pharmaceuticals.
SUBSTANCE: invention relates to compounds of general formula (I) and pharmaceutically acceptable salts thereof, wherein in formula (I) R1 denotes -NR5R6, -OR5 or -SR5; X is CR4, Y is N; R2 is selected from a group consisting of C1-C6 alkoxy or C1-C6 alkyl sulfanyl; R3 is selected from -N(Rv)RuN(Ry)(Rz), -ORuOR6, -ORuN(Ry)(Rz) and -SRuN(Ry)(Rz); R4 and R'4 are each selected from the group consisting of hydrogen, halogen, C1-C6alkyl and C1-C6haloalkyl; R5, R6, Ry, Rz are as specified in claim 1; Ru is C1-C6alkylene; Rv is selected from hydrogen and C1-C6alkyl. Invention also relates to specific compounds specified in cl. 7 of the formula, to a pharmaceutical composition and to use for preparing a medicinal agent.
EFFECT: technical result is compounds of formula (I) and specific compounds of claim 7 as EGFR and/or HER2/ErbB2 PTK inhibitors.
11 cl, 19 tbl, 26 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | 2011 |
|
RU2598852C2 |
| PROTEIN TYROSINE KINASE MODULATORS AND METHODS OF USE | 2014 |
|
RU2656591C2 |
| SUBSTITUTED N-{3-[4-(1-METHYL-1H-INDOL-3-YL)PYRIMIDIN-2-YLAMINO]-4-METHOXYPHENYL}-AMIDES AS MODULATORS OF EGFR, APPLICABLE FOR TREATING CANCER | 2015 |
|
RU2606949C9 |
| INHIBITOR OF EGFR AND PRODUCTION AND USE THEREOF | 2015 |
|
RU2702631C2 |
| NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | 2011 |
|
RU2585177C2 |
| ANILINE PYRIMIDINE DERIVATIVES AND USE THEREOF | 2016 |
|
RU2734849C2 |
| COMPOUNDS AND COMPOSITIONS FOR MODULATING KINASE ACTIVITY OF EGFR MUTANTS | 2015 |
|
RU2822389C2 |
| PYRIMIDINE DERIVATIVES | 2008 |
|
RU2455994C2 |
| COMPOUNDS AND A COMPOSITION FOR MODULATING THE KINASE ACTIVITY OF EGFR MUTANTS | 2015 |
|
RU2727700C2 |
| DERIVATIVES OF 2,4-SUBSTITUTED PHENYLENE-1,5-DIAMINE AND THEIR USES, PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS OBTAINED FROM THEM | 2015 |
|
RU2649001C1 |
